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Introduction
Follicular lymphoma (FL) is the second most common 
non- Hodgkin lymphoma (NHL) and makes up 22% of 
NHL cases according to the NHL Lymphoma Classification 
Project [1]. FL is characterised by multiple relapses and 
progressively shorter response durations as the number of 
therapies increases. Despite the development of numerous 
treatment strategies to reduce the risk of progression, opti-
mal therapeutic strategies for patients with FL remain 
undefined. Multiple studies have demonstrated a clinical 
benefit in treating patients with FL with the radioimmu-
notherapy (RIT) regimen yttrium- 90 ibritumomab tiuxetan 
(90Y- IT) [2–4], including the phase III First- Line Indolent 
Trial (FIT): FIT was a prospective, randomised trial that 
compared observation versus consolidation therapy with 
90Y- IT in patients with previously untreated advanced FL 
who achieved partial response (PR) and complete response 
(CR) to first- line induction therapy [5]. 90Y- IT was highly 
effective with no unexpected toxicities, producing a statisti-
cally longer time to progression in both PR and CR patients. 
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Abstract
Radioimmunotherapy (RIT) after an induction phase with conventional chemo-
immunotherapy became an attractive strategy of consolidation for patients with 
advanced follicular lymphoma: in particular, in many studies RIT was represented 
by yttrium- 90- ibritumomab tiuxetan (90Y- IT). Independently by the different 
front- line treatment, updates on the long- term follow- up of these studies are 
needed because the disease course of follicular lymphoma is characterised by 
multiple relapses and progressively shorter durations of response. We report 
updated long- term efficacy and toxicity results of a multicenter phase II study 
on sequential treatment with four cycles of fludarabine, mitoxantrone, and 
rituximab followed by 90Y- IT as front- line therapy for untreated patients with 
intermediate/high- risk follicular lymphoma. With a median follow- up of 
84 months, only 19/49 (38.8%) complete response patients relapsed, yielding 
an estimated long- term disease- free survival of 62.6%. The 7- year overall survival 
was 72.7%. Four (7.3%) second acute myeloid leukemia occurred, with a median 
time following RIT of 42 months. A relevant patients’ responsiveness to sub-
sequent therapies occurred: approximately 65% of relapsed patients obtained a 
good clinical response after the second- line treatment. These data represented 
the first evidence of a real role even in the long period of 90Y- IT after a 
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chemotherapy with/without rituximab reported high rate 
of conversion from PR to CR with significant improve-
ments in progression- free survival (PFS) [6–9]. Moving 
from these results, and on the basis of the innovative 
approach that combines induction chemoimmunotherapy 
and subsequent consolidation with 90Y- IT with the short-
ening of chemotherapy duration (to decrease the potential 
long- term side effects of antiblastic drugs), some reports 
have demonstrated interesting results [10–13]. One of these 
represented our experience: a prospective, multicenter, 
nonrandomised phase II trial of short fludarabine, mitox-
antrone, and rituximab (FMR) induction (only four cycles 
instead of the conventional six) followed by 90Y- IT in 
untreated, intermediated/high- risk FL patients was con-
ducted to evaluate efficacy and safety of this combined 
regimen [13].Long- term evaluations of both efficacy and 
safety now are needed to best integrate this option into 
current FL treatment algorithms: we now report updated 
results of the study after a median follow- up of 7 years.
Patients­and­Methods
Patients
A total of 55 patients with intermediate/high- risk FL were 
enrolled between December 2006 and November 2008, at 
three Italian institutions. The criteria for patient eligibility 
were previously reported [13]. Patients’ characteristics are 
summarised in Table 1. Briefly, patients had to be previ-
ously untreated and to present with clear indication to 
therapy; they had to have a WHO performance status of 
two or less and Follicular Lymphoma International 
Prognostic Index (FLIPI) [14] score ≥2. All diagnostic 
biopsies were reviewed in accordance with the WHO clas-
sification [15]; the Ki- 67 value ranged from 5% to 20%.
All patients were notified of the investigational nature 
of this study and signed a written informed consent 
approved in accordance with institutional guidelines, 
including the Declaration of Helsinki; the study was 
approved by each institutional review board.
Study­design
Treatment schedule was the following: 25 mg/m2 standard 
i.v. fludarabine on day 1–3, 10 mg/m2 i.v. mitoxantrone 
on day 2, and rituximab (375 mg/m2 on day 1) admin-
istered on a 28- day schedule for four cycles. After the 
completion of the fourth cycle of FMR regimen, patients 
were restaged by computed tomography (CT) scan, posi-
tron emission tomography (PET) scan, and bone marrow 
biopsy. Patients were eligible for 90Y- IT if at least in PR 
after induction, with normal platelet and granulocyte counts 
and a bone marrow infiltration ≤25%.
After the restaging procedures, eligible patients received 
one course of 90Y- IT within 12 weeks. It consisted of an 
infusion of rituximab at 250 mg/m2 on day 1 and a sub-
sequent infusion at the same dose on day 8; this second 
infusion of rituximab was then followed by a weight- based 
dose of 90Y- IT, administered at the dose of 11.1 MBq/kg 
(0.3 mCi/kg) for patients with pretreatment platelet counts 
ranging from 100 × 109/L to 149 × 109/L, and (0.4 mCi/
kg) for those with counts of 150 × 109/L or higher (90Y- 
IT was routinely administered on an outpatient basis).
Follow-­up­procedures
Strict follow- up procedures were shared among the three 
hospitals at the time of the start of the study. The original 
protocol was amended to extend follow- up until 8 years 
from end of treatment. Disease status was evaluated again 
3 months after RIT through physical examination, bone 
marrow biopsy (if still positive after induction chemo-
therapy), CT and PET scan; other clinically relevant 
Table 1. Patients’ characteristics (n = 55).





























Intermediate risk (2) 36
High risk (≥3) 19
LDH, lactate dehydrogenase; B symptoms, fever, weight loss, night 
sweats, pruritus sine materia; FLIPI, Follicular Lymphoma International 
Prognostic Index.
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information, such as the development of febrile neutropenia, 
the use of antibiotics or G- CSF or blood transfusion during 
cytopenia, and the presence of any extrahematologic toxic-
ity, were recorded. Patients’ follow- up assessment included: 
blood count and physical examination every 3–4 months 
for the first 2 years and then every 6 months for the fol-
lowing 3 years, CT scan every 6 months for the first 2 years, 
followed by physical examination and annual imaging studies 
with CT or PET/CT up to 8 years from treatment comple-
tion. The determination of tumor response was based on 
the revised response criteria for malignant lymphoma [16].
Endpoints
Endpoints of long- term efficacy were PFS, disease- free 
survival (DFS) and overall survival (OS) (16). Endpoints 
of late toxicity were the incidence and the time of occur-
rence of second malignancy both hematologic and non-
hematologic. The crude incidence of second malignancies 
was calculated as the proportion of patients diagnosed 
with second malignancy in the entire study population.
Analyses were conducted on an intention to treat basis.
Results
At the end of the entire treatment regimen (four cycles 
of FMR regimen plus 90Y- IT), 49 out of 55 (89.1%) patients 
obtained CR. Median follow- up at the time of the last 
analysis was 84 months (range, 10–144 months). All patients 
completed the scheduled follow- up period. Seven- year PFS 
was estimated to be 50.1% (Fig. 1), and DFS was 62.6% 
(Fig. 2); 7- year OS was estimated to be 72.7% (Fig. 3), 
with eight deaths. There were not distinguishing charac-
teristics between responder and no- responder patients; no 
statistically significant difference was observed between 
patients with FLIPI 2 or higher, either in the type of 
response or in the long- term outcomes.
Regarding the late hematological side effects, second 
malignancies occurred in four (7.3%) patients: all of them 
reported a secondary acute myeloid leukemia (AML), 
developed after 36, 38, 45, and 52 months following RIT, 
respectively (all these four patients died). No late solid 
tumor malignancies occurred.
Currently, 30 patients (61.2%) are in continuous CR 
after >5 years of follow- up. Nineteen patients relapsed 
during the follow- up period and four patients died due 
to lymphoma progression. All the 19 relapsed patients 
underwent second- line treatment and received rituximab 
as part of their second- line therapy mainly combined with 
chemotherapy regimens, including: bendamustine (nine 
cases); doxorubicin, cyclophosphamide, vincristine, and 
prednisolone (CHOP) (six cases); cyclophosphamide, vin-
cristine, and prednisolone (CVP) (two cases); or ifosfamide, 
epirubicin, and etoposide (IEV) (two cases). Subsequently, 
high- dose therapy with rescue of peripheral stem cells 
was performed in five patients. No failed attempts at cell 
harvesting were observed. The overall response rate to 
second- line therapy was 63.2% (12/19 patients).
Discussion
One of the most important challenges for new FL thera-
peutic options is that they should increase survival without 
increasing toxicity. The majority of FL patients have 
advanced disease at diagnosis; in this subset, the advent 
of rituximab as part of the front- line approach has changed 
Figure 1. Progression- free survival.
Figure 2. Disease- free survival.
Figure 3. Overall survival.
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the conception of FL treatment. There is no international 
consensus on the optimal front- line chemotherapy regimen 
for patients with advanced FL, and currently, the most 
widely used front- line treatment for patients with FL is 
rituximab in combination with chemotherapy [17–20].
On the other side, radioimmunotherapy after the induc-
tion phase with conventional chemoimmunotherapy 
became an attractive strategy of consolidation: in particular, 
in many studies, radioimmunotherapy was represented by 
90Y- IT [5, 10–13].
Independently by the different front- line treatment, it 
should be very important to have an update on the long- 
term follow- up of these studies because the disease course 
of FL is characterised by multiple relapses and progres-
sively shorter durations of response with a median survival 
of approximately 10 years [21].
For this reason, our report updates long- term efficacy 
and toxicity results of a sequential treatment with four 
cycles of FMR followed by 90Y- IT as front- line therapy 
for untreated patients with intermediate/high- risk FL.
With the potential benefit of reducing induction cycles 
from 6 to 4 achieving the same results [6] and with the 
chance of reducing the cumulative toxicity of the two 
additional cycles of conventional chemotherapy, this thera-
peutic regimen confirms its real role even in the long- term 
period. Similar updates are very rare [22].
With a median follow- up of 84 months, only 19/49 
(38.8%) CR patients relapsed, yielding an estimated long- 
term DFS of 62.6%; particularly, the last relapse in terms 
of timing was observed within 36 months showing a 
plateau of DFS curve after this point. Furthermore, it is 
important to remember that patients were intermediate 
or high- risk according to FLIPI score.
There is a lively debate in literature regarding the issue 
of safety of this regimen. We shortened the course of 
fludarabine from 6 to 4 cycles and this could be the reason 
of generally mild and transient toxic effects during and 
immediately after treatment. No infections occurred [13]. 
The AML incidence with conventional dose chemotherapy 
or radiotherapy ranges from 0% to 12% in literature and 
numerous fundamental questions remain unanswered with 
regard to the actual (as opposed to the actuarial) incidence 
of treatment- related AML (tAML), the etiology and the 
definition of the disease, and the additional patient or 
treatment- related risk factors [23]. tAML are clinically and 
cytogenetically distinct from de novo cases: a potential 
bias of our report is that we did not distinguish between 
de novo and treatment- related AML cases. We chose to 
report crude incidence because we were not able to con-
sider all the competing risks and due to the fact that 
there is a degree of ambiguity with regard to the statistical 
methodology used in the literature; several results are often 
not comparable. However, the crude incidence of t- AML 
has been reported to range from 0% to 12% with con-
ventional dose chemotherapy or radiotherapy [24] and the 
present 7% is within this range. Furthermore, in our pre-
vious reports on 90Y- IT no AML occurred so far [7, 25].
So far it is not clear if fludarabine combined with 90Y- 
IT could really increase the number of leukemias. It is 
possible that a fludarabine- free chemotherapy could further 
reduce the number of leukemias and safety concerns 
remains a matter of debate.
A relevant patients’ responsiveness to subsequent thera-
pies was registered; approximately 65% of relapsed patients 
obtained a good clinical response after the second- line 
treatment. In this subset, the consolidation therapy with 
90Y- IT did not appear to rule out any second- line treat-
ment approach, including harvesting an autologous stem 
cell graft and subsequent autologous stem cell transplanta-
tion (as noted previously also in a specific report) [26].
In conclusion, in this 7- year update report our data 
confirmed an impressive DFS higher than those reported 
for the other chemoimmunotherapies also in long- term 
follow- up although patients were intermediate/high- risk 
FLIPI and underwent induction phase with a short course 
chemoimmunotherapy.
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